Cutting Edge AI-Integrated Collaborative Drug Discovery & Development
Covantage Therapeutics is a next-generation biotechnology company delivering an AI-integrated, end-to-end drug discovery and development platform that unifies cancer biology intelligence, clinical chemistry, computational modelling, and advanced preclinical validation and development.A Unified Intelligence Platform for Precision Drug Discovery
Contact Us
A Unified Intelligence Platform for Precision Drug Discovery
Our mission is to dramatically compress discovery timelines, reduce attrition, and improve clinical success rates for programs addressing high-unmet medical needs.
At the core of Covantage is a multi-layered Proprietary AI platform purpose-built to transform fragmented biological and chemical data into decision-ready insights—from target discovery to translational readiness.
A Unified Intelligence Platform for Precision Drug Discovery is built on a deeply integrated Cancer Biology and Clinical Chemistry knowledge foundation. Our platform brings together highly curated biological and chemical data layers to create a robust, trustworthy base for AI-driven discovery. On the biology side, it integrates clinical and patient-derived data, mutation landscapes, disease biology repositories, drug response profiles, and detailed mechanism-of-action datasets, all reinforced by extensive in-vitro and in-vivo experimental evidence. In parallel, the chemistry and molecular intelligence layer incorporates structural and functional chemical databases, physicochemical and ADME parameter libraries, and comprehensive compound–target interaction datasets. By harmonizing these diverse data sources into a single intelligence backbone, the platform delivers context-aware, biologically grounded predictions that reflect real disease biology and molecular behavior—enabling confident decision-making without reliance on opaque, black-box models.
Our Vision
Our vision is to become the world’s leading innovation hub for AI-enabled drug discovery, mechanistic biology, biochemistry, and translational development, transforming complex, high-dimensional biological and chemical data into clinically meaningful insights and life-changing therapies. We aim to redefine how medicines are discovered by unifying cancer biology intelligence, molecular and biochemical understanding, and predictive AI within a single, integrated platform.
By seamlessly bridging advanced computational modelling with state-of-the-art preclinical and biochemical platforms, we accelerate the journey from target discovery to clinical readiness. Our approach enables deep mechanistic understanding of disease pathways, drug–target interactions, and biomarker dynamics—ensuring that therapeutic hypotheses are not only innovative, but biologically sound and experimentally validated.
Through translational intelligence, including patient stratification, biomarker-driven decision making, and virtual clinical modelling, we de-risk development early and improve the probability of clinical success. This allows us to minimize late-stage failures, shorten development timelines, and deliver therapies that are safer, more effective, and precisely matched to patient populations.
Driven by collaborative science, rigorous validation, and scalable innovation, we empower biotech, pharma, and academic partners worldwide to move beyond trial-and-error drug discovery toward a future defined by speed, precision, and predictable clinical outcomes—ultimately translating scientific insight into real impact for patients.
What We Offer
Novel Drug Discovery &
Development
We deliver deep, AI-driven understanding of cancer biology by integrating multi-omics data, patient genomics, clinical chemistry, and disease biology into a unified intelligence layer. Our platform systematically maps mutations, signalling pathways, and molecular networks to identify high-confidence targets, clinically relevant biomarkers, and disease-specific vulnerabilities. By contextualizing genomic data with real biological and clinical evidence, we transform complex datasets into actionable insights that guide precision therapy development, patient stratification, and indication selection.
- Target identification & Validation
- Drug Repurposing & Combinations
- Drug Repositioning
- Biomarker Profiling
- Patient Stratification
- Indication Selection
- Companion Diagnostics
- Virtual Clinical Trials
AI-Integrated Mechanistic Biology & Clinical Chemistry Platform validated in our Preclinical Development
Our AI-powered discovery engine bridges computational prediction with rigorous preclinical science. We enable rational drug repurposing, novel target Identification, validation, and mechanism-of-action driven molecule prioritization through virtual screening, toxicity profiling, and predictive efficacy modeling. These insights are seamlessly translated into in-vitro and in-vivo validation using disease-relevant models, ensuring early go/no-go decisions are grounded in biology. This integrated approach reduces attrition, accelerates timelines, and significantly lowers development risk before entering costly clinical stages.
- Virtual Screening (In-Vitro)
- Virtual Screening (In-Vivo)
- Toxicology Profiling/ Virtual Screening
- Cardiotoxicity screening
- Carcinogenicity screening
- Hepatotoxicity
- Neurotoxicity
- Allergic Reactions and Side Effects Matrix
- Preclinical Development including LI/LO and IND enabling studies.
Translational & Clinical Development Acceleration
We extend discovery insights into the clinic through translational intelligence that links molecular biology to patient outcomes. Our platform supports virtual clinical trials, companion diagnostics development, and rational drug-combination strategies to optimize clinical success. By aligning biomarkers, patient selection, and therapeutic hypotheses early, we help partners minimize clinical failure rates, shorten development cycles, and achieve meaningful differentiation in competitive therapeutic landscapes.
- Virtual Clinical Trials and data validation to identify right patient for right Trials
- Inclusion/Exclusion Development
- Companion Diagnostics
- Drug Combination Trials
- Biomarker Validation
Why Covantage Therapeutics
Integrated AI +
Wet-Lab Ecosystem
Faster Discovery Cycles,
Higher Predictive
Accuracy
End-to-End
Capabilities
From Molecular
Insights to IND‑Ready
Packages
Focus on High‑
Impact Diseases
Oncology, Autoimmune,
CNS
Collaborative
Approach
Partnering with Biotech,
Pharma & Academic
Institutes
Our Collaboration Model
We bring science, AI, and execution together to convert
innovation into tangible therapeutic value.
Co-Development Partnerships
We collaborate closely with partners to advance drug discovery programs from early target identification through preclinical development. Our co-development model combines your domain expertise with our computational biology, assay development, and wet-lab capabilities to accelerate progress while maintaining full transparency, shared decision-making, and clearly defined milestones.
Joint IP Creation
Our joint IP framework enables fair and transparent ownership of discoveries made together, including novel targets, compounds, and biomarkers. We establish clear IP governance from the start to ensure both parties benefit equitably and can confidently advance, license, or commercialize the resulting innovations.
Risk-Sharing Discovery Models
For high-risk or early-stage programs, we offer shared-risk models that reduce upfront costs and align incentives. Through milestone-based structures or success-linked payments, we help partners pursue promising science while minimizing financial burden and increasing the likelihood of downstream success.
Service-Based Preclinical Programs
Partners can access our preclinical platform through modular service offerings tailored to their needs — from custom assays and organoid models to PK/PD, toxicity, and biomarker studies. This flexible approach allows companies of any size to tap into advanced capabilities without long-term commitment or infrastructure investment.